Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes

• by Shuxia Zhang, Yi Chen, Haojie Qin, Jing Chen, Chunrong Chen, Xuemei Wu, Min Chen, Jiajun Lin, Fenge Yang, Meijuan Huang

• July 14, 2026

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

• by Luca Paruzzo, Emeline R. Chong, Elise A. Chong, Zhixuan Zheng, Puneeth Guruprasad, Daniel J. Landsburg, Sunita D. Nasta, Federico Stella, Ranjani Ramasubramanian, Vitor B. de Souza, Mohannad H. Alkhatib, Matthew Ho, Antonio Imparato, Gregory M. Chen, Don L. Siegel, Gabriela Plesa, Anlan Dai, Shane Mackey, Priyamvada Das, Peter Michener, Julie Jadlowsky, Frederic D. Bushman, Vrutti Patel, Alberto Carturan, Ellen B. Napier, Vanessa E. Gonzalez, Danuta Jarocha, Rong Xu, Bruce L. Levine, Patrizia Porazzi, Noelle Frey, David L. Porter, Jakub Svoboda, Joseph A. Fraietta, Carl H. June, Stephen J. Schuster, Marco Ruella

• August 26, 2026

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

• by Yi Bao, Lei Zhang, Fenfen Jiang, Juanfen Mo

• September 1, 2026

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

• by

• August 26, 2026

• 3 min